For its fourth fiscal quarter (ending December 31), Travere Therapeutics Inc (NASDAQ: TVTX) has reported a -37% decline in E.P.S. from $-1.16 a year ago to $-0.73 in the current quarter. E.P.S. were $-4.06 for the latest four quarters through December 31 versus $-5.07 for the same period a year ago — a decline of -20%.
Recent Price Action
On 2/20/25, Travere Therapeutics Inc (NASDAQ: TVTX) stock increased 1.1%, closing at $23.58. This advance was accompanied by normal trading volume. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -0.7% during the last week.
Current PriceTarget Research Rating
Travere Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Travere Therapeutics has a very low Appreciation Score of 6 but a very high Power Rating of 97, with the Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment